Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled Trial

Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use

(2019) Mengzhen Liu et al.   NATURE GENETICS

Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?

(2019) Orestis A Panagiotou et al.   NICOTINE & TOBACCO RESEARCH

Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES

(2018) Robert West et al.   ADDICTION

Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women

(2018) Paulo Roberto Xavier Tomaz et al.   BMC Medical Genetics

Pharmacogenetic Optimization of Smoking Cessation Treatment

(2017) Meghan J. Chenoweth et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial

(2016) Heather E. Tulloch et al.   BMC Medicine

Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks

(2016) Timothy B. Baker et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial

(2016) Robert M Anthenelli et al.   LANCET

Pathways to smoking behaviours: biological insights from the Tobacco and Genetics Consortium meta-analysis

(2016) C C Minicã et al.   MOLECULAR PSYCHIATRY

Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States

(2016) Paige Maas et al.   JAMA Oncology

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation

(2015) Li-Shiun Chen et al.   DRUG AND ALCOHOL DEPENDENCE

Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking

(2015) Rachel F. Tyndale et al.   PLoS One

Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial

(2015) Caryn Lerman et al.   Lancet Respiratory Medicine

Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers

(2014) A Z X Zhu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Interplay of Genetic Risk Factors (CHRNA5-CHRNA3-CHRNB4) and Cessation Treatments in Smoking Cessation Success

(2012) Li-Shiun Chen et al.   AMERICAN JOURNAL OF PSYCHIATRY

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies

(2012) Andrew W. Bergen et al.   Pharmacogenetics and Genomics

Genome-wide meta-analyses of smoking behaviors in African Americans

(2012) S P David et al.   Translational Psychiatry

Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy

(2011) Jane E. Sarginson et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Unknown

(2010) Jed Rose et al.   MOLECULAR MEDICINE

Optimal Serum Cotinine Levels for Distinguishing Cigarette Smokers and Nonsmokers Within Different Racial/Ethnic Groups in the United States Between 1999 and 2004

(2008) Neal L. Benowitz et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Variants in Nicotinic Receptors and Risk for Nicotine Dependence

(2008) Laura Jean Bierut et al.   AMERICAN JOURNAL OF PSYCHIATRY

Development and Validation of a Lung Cancer Risk Prediction Model for African-Americans

(2008) C. J. Etzel et al.   Cancer Prevention Research